

**Meeting Minutes
Vaccine Committee Meeting
March 7, 2024; 12:00-1:00 p.m. PT**

I. Attendance. This meeting was conducted solely by webinar. Participating in all or part of the meeting were the following individuals:

<p>8 <u>Members</u></p> <p>9 Ed Marcuse, MD, Emeritus Professor of</p> <p>10 Pediatrics, University of Washington, <i>Chair</i></p> <p>11 Amy Carter, MD, Allegro Pediatrics</p> <p>12 John Dunn, MD, MPH, Kaiser</p> <p>13 Libby Page, MPH, King County Public Health</p> <p>14 Jeff Gombosky, Pharmaceutical Research and</p> <p>15 Manufacturers of America</p> <p>16 Carrie Jenner, MD, Pierce County Immunization</p> <p>17 Coalition (PCIC)</p> <p>18 Janel Jorgenson, Washington Department of Health</p> <p>19 Jamilia Sherls-Jones, DNP, MPH, Washington</p> <p>20 Department of Health</p> <p>21 Amy Person, MD, Benton-Franklin Health District</p> <p>22 Kristi A. Rice, MD, Providence</p>	<p>24 <u>WVA</u></p> <p>25 Julia G. Zell, MA, Esq., Executive Director</p> <p>26 Cheri Cagle, Stakeholder Liaison</p> <p>27 Sherri Zorn, MD, WVA Consultant</p> <p>28</p> <p>29 <u>Helms & Company, Inc.</u></p> <p>30 Patrick Miller, MPH, WVA, Administrative</p> <p>31 Director</p> <p>32 Ashley Ithal, MPH, Project Support Leader</p> <p>33</p> <p>34 <u>Other</u></p> <p>35 Breelyn Young, GSK</p> <p>36 Chris Schattenkerk, Moderna</p> <p>37 Lisa Templeton, Informed Choice WA</p> <p>38 Natalie Chavez, Public Attendee</p>
---	---

II. Summary of Actions Taken and/or Recommended

Actions Taken (votes adopted)

- i. To approve Vaccine Committee meeting minutes (April 27, 2023).
- ii. To approve Special Purpose Vaccine Committee meeting minutes (September 21, 2023).

III. Minutes

Welcome and Introductions

At 12:06 p.m. Dr. Marcuse called the meeting to order. Ms. Zell announced that the meeting would be recorded for the benefit of the minute taker, to be deleted once the minutes are approved.

Calendar Consent Items

Dr. Marcuse asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously

- i. **VOTED: To approve the Vaccine Committee meeting minutes (April 27, 2023).**
- ii. **VOTED: To approve the Special Purpose Vaccine Committee meeting minutes (September 21, 2023).**

IV. Nirsevimab Update

Ms. Jorgenson provided an update on the ordering process including challenges with product shortages for nirsevimab this season. She reminded the group that a week into provider ordering the DOH was notified by the CDC of product shortages impacting availability of nirsevimab this season. Ms. Jorgenson reported that DOH has distributed approximately 30,000 doses of nirsevimab to date. RSV season in Washington ends March 31, and much of the product ordered this season can be held and used next season due to a longer shelf life. The DOH noted that they are interested in learning more from providers about the demand in practice and uptake of this product. Dr. Carter noted that next year should be more successful in terms of ordering and planning early in the season. Dr. Dunn reiterated that sentiment.

Ms. Sherls-Jones reported that to date there have been approximately 7,300 people who have received a maternal dose of Abrysvo. Ms. Sherls-Jones shared the RSV coverage dashboard link (<https://doh.wa.gov/data-and-statistical->

70 [reports/diseases-and-chronic-conditions/communicable-disease-surveillance-data/respiratory-illness-data-dashboard](https://www.wva.org/reports/diseases-and-chronic-conditions/communicable-disease-surveillance-data/respiratory-illness-data-dashboard))
71 with the Committee.

72
73 Dr. Dunn reported that the legislative change to the WVA’s authorizing statute has passed the House and Senate and
74 is awaiting signature from Governor Inslee.

75
76 **V. Respiratory Vaccine Distribution and Challenges**

77
78 Influenza Vaccine

79 Ms. Jorgenson reported that the overall uptake for influenza vaccination is approximately 30%, which remains similar
80 to last season and lower than pre-pandemic levels. Ms. Shelrs-Jones added that approximately 27% of children
81 between 6 months and aged 17 received at least one dose of influenza vaccine for the season so far. Dr. Carter noted
82 that her practice privately purchased influenza vaccine to support mass drive-through vaccination events. She noted
83 they administered approximately 43,000 doses this year which is 2% less than the previous season.

84
85 COVID-19 Vaccine

86 Dr. Marcuse reported that he was unaware of any new information for childhood COVID-19 vaccination in the past
87 few months. Dr. Zorn reported that she had heard from some adults that they thought the COVID-19 vaccine was part
88 of a combination vaccine, and she subsequently provided education that COVID-19 vaccines were separate.

89
90 **VI. Assessment of MMR Coverage by Geographic Area**

91
92 Ms. Jorgenson shared an overview of MMR coverage. She reported that 77.6% of school aged children
93 (7-18 years of age) have received two or more doses of MMR as of February 29, 2024. There was concern
94 expressed by some Committee members regarding the low uptake rates. Ms. Ithal will distribute this presentation to
95 the Committee.

96
97 **VII. WVA Updates**

98
99 Provider Outreach Efforts

100 Ms. Zell reported that the WVA is attempting to identify and conduct outreach to different provider types that do not
101 currently complete the WVA dosage based assessment (DBA). Outreach to enrolled hospitals has been completed,
102 and the WVA expects active participation in assessment generation by July 1, 2024. Additional provider types that
103 are not currently completing the DBA but are receiving state-supplied vaccine include direct care practices, school-
104 based health clinics, local health jurisdictions, the mobile clinic, and pharmacies. The WVA Board has concerns
105 about providing vaccines to these provider types without active completion of the DBA process. Ms. Zell reported
106 that there is a current policy exemption for local health jurisdictions from completing the DBA process, and a policy
107 will be developed for the other provider types. Ms. Zell noted that the WVA is working closely with the DOH on
108 provider outreach efforts.

109
110 **VIII. Public Comments**

111
112 Public comments were heard.

113
114 **IX. Closing**

115
116 The meeting adjourned at 1:00 p.m. PT.